CTLA4 and cancer: Currently, the most relevant immunological checkpoints in cancer immunotherapy are cytotoxic T- lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) expressed in T lymphocytes and programmed cell death ligand 1 (PD-L1) expressed on the cancer surface.